Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators aim at characterizing neuropsychiatric consequences of heart transplantation (HTX) and at assessing the impact of depressive symptoms after HTX on mortality and cardiac allograft vasculopathy (CAV).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants from former study 1 | Surviving participants from a former study called 'Psykosomale faktorer hos pasienter med hjertesvikt og hos hjertetransplanterte' | ||
| Participants from former study 2 | Surviving participants, included at the Norwegian centre, from a study called 'Scandinavian Heart Transplant Everolimus De Novo Study with Early Calcineurin Inhibitor Avoidance (SCHEDULE)' (NCT01266148) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Psychiatric morbidity | Psychiatric diagnoses by clinician and self-rapport | At time of enrollment |
| Cognitive function | Neuropsychological assessment | At time of enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| All cause mortality | Time since enrollment in former study; i.e. approximately 14 years (study 1) and approximately 3 years (study 2) | 14 and 3 years respectively |
| Cardiac allograft vasculopathy |
| Measure | Description | Time Frame |
|---|---|---|
| Cerebral pathology | MRI of the brain | At time of enrollment |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Surviving participants from two former studies
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ira R. Hebold Haraldsen, MD/dr philos | Oslo University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oslo University Hospital | Oslo | 0424 | Norway |
Not provided
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
| D003072 | Cognition Disorders |
| ID | Term |
|---|---|
| D019965 | Neurocognitive Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Serum and plasma
Time since enrollment in former study; i.e. approximately 14 years (study 1) and approximately 3 years (study 2)
| 14 and 3 years respectively |